ALKS Q2 2023 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$617M+123.5% YoY

Gross Profit

$554M89.8% margin

Operating Income

$281M45.6% margin

Net Income

$237M38.4% margin

EPS (Diluted)

$1.38

QoQ Revenue Growth

+114.7%

Cash Flow

Operating Cash Flow

$216M

Free Cash Flow

$206M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$907M

Stockholders' Equity

$1.3B

Cash & Equivalents

$666M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$617M	$276M	+123.5%
Gross Profit	$554M	$218M	+154.4%
Operating Income	$281M	-$34M	+916.3%
Net Income	$237M	-$30M	+886.7%

Revenue Segments

Manufacturing Revenue

$32M100%